I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ ...

Retrieved on: 2021-03-30 12:00:00

Tags for this article:

Click the tags to see associated articles and topics

I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ .... View article details on hiswai:

Excerpt

Preclinical studies demonstrate that TJ-CD4B/ABL111 has superior anti-tumor property as compared to the two monoclonal antibodies when acting ...

Article found on: finance.yahoo.com